Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Optic Neuropathy
Interventions: magnetic resonance image (MRI), Optical Coherence Tomography (OCT); Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Heart Disease, Heart Failure With Preserved Ejection Fraction, Exercise Intolerance, Pulmonary Hypertension
Interventions: Nitrite, Saline Placebo for Nitrite; Drug
Lead sponsor: Barry Borlaug; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: SPARC0913; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Choroidal Melanoma
Interventions: ranibizumab; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pre-Eclampsia, Diphtheria, Tetanus and Pertussis Vaccine Reaction
Interventions: Tdap Vaccine Administration; Drug
Lead sponsor: Institute of Arthritis Research; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Idaho Falls, Idaho

Conditions: Glaucoma, Vision Impairment and Blindness, Cataract, Diabetic Retinopathy, Eye Diseases
Interventions: Enhanced Intervention Using Patient Navigators, Usual Care; Behavioral · Other
Lead sponsor: Columbia University; Other
Eligibility: 40 Years and older
Enrollment: 749 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Obese, Elevated Blood Pressure
Interventions: Mat Pilates training; Behavioral
Lead sponsor: Marymount University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Hypertension
Interventions: Standard and One-time Training, Standard and Practice Facilitation, High-intensity and One-time Training, High-intensity and Practice Facilitation; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypertension
Interventions: clevidipine; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Open-Angle Glaucoma
Interventions: iStent plus Cataract Surgery, Cataract surgery only; Device · Procedure
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 31
States / cities: Beverly Hills, California • Petaluma, California • Sacramento, California + 27 more

Conditions: Preeclampsia, Hypertensive Disorders of Pregnancy (HDP), Pregnancy Complications, Aspirin Prophylaxis
Interventions: Clinician notification of elevated preeclampsia risk; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Eyes, Eye Diseases
Interventions: Topcon DRI OCT Triton (plus), 3D OCT-1 Maestro; Device
Lead sponsor: Topcon Medical Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Willmar, Minnesota

Conditions: Thyroid Eye Disease, Ocular Hypertension, Glaucoma
Interventions: Prostaglandin Analog, Timolol; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pulmonary Arterial Hypertension
Interventions: Fulvestrant; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sleep Apnea, Obstructive, Hypertension
Interventions: Positive Airway Pressure; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV, CVD, Metabolic Disease
Interventions: LEARN 2 Platform; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Orange, Connecticut

Conditions: Pulmonary Arterial Hypertension (PAH)
Interventions: LIQ861 (treprostinil) inhalation powder; Combination Product
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Georgia

Conditions: Hypertension in Pregnancy, Postpartum Preeclampsia
Interventions: Education provided via a video format; Other
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hypertensive Disorder of Pregnancy, Sleep-disordered Breathing
Interventions: Not listed
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Gestational Hypertension, Preeclampsia, Chronic Hypertension Complicating Pregnancy
Interventions: App-based remote blood pressure monitoring, text-message based remote blood pressure monitoring; Behavioral
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Pulmonary Arterial Hypertension
Interventions: Ambrisentan, Placebo, Sildenafil, Tadalafil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 30
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Conditions: Sleep Apnea, Obstructive, Hypoxia, Hypercapnia, Sleep Disorders, Obesity, Hypertension, Coronary Artery Vasospasm, Right Ventricular Overload, Left Ventricular Function Systolic Dysfunction, Ventricular Hypertrophy
Interventions: Clinically prescribed CPAP therapy; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 50 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Part 1 - Healthy Volunteers, Part 2 - Patients With Hypertension
Interventions: LFF269, Placebo to LFF269; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Intracranial Pressure Increase, Cerebral Edema
Interventions: Not listed
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New Orleans, Louisiana

Search by objective public record fields.

Biomechanics of Optic Neuropathy

Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction

Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36

Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)

Mat Pilates and Vascular Function in Obese Females

Comparing Hypertension Remote Monitoring Evaluation Redesign

Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)

A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma

Clinician Notification to Increase Aspirin Prophylaxis for Preeclampsia Prevention

Triton Agreement and Precision Study

The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.

Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension

Mechanisms for Individual Differences in Hypertension in Obstructive Sleep

Theoretically Informed Behavioral Intervention

A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag

Assessment of Postpartum Education to Improve Compliance

Association of Hypertensive Disorder of Pregnancy With Sleep-disordered Breathing.

App-based Remote Blood Pressure Monitoring

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

"Reversibility of Cardiovascular Injury With CPAP Use: Mechanisms Involved"

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

Noninvasive Monitoring of Cerebral Blood Flow Autoregulation